Search research articles
Contact Us
Filters
Showing results (371-380 of 386) with videos related to
Page
of 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
Samuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Daniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
Biorxiv : the Preprint Server for Biology
|
February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer
A Mandl, S Jasmine, Teg Krueger, et al.
Cancer
|
December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
The Lancet. Oncology
|
August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
European Urology
|
December 20, 2016
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na, S Lilly Zheng, Misop Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Page
of 39
Search research articles
Search
Showing results (371-380 of 386) with videos related to
Sort By:
Page
of 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
Samuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
Future Oncology (London, England)
|
April 11, 2019
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Hiten D Patel, Maneka Puligandla, Brian M Shuch, et al.
BMC Cancer
|
June 4, 2020
A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
Hamza Hasan, Matthew P Deek, Ryan Phillips, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 5, 2016
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Daniel L Hertz, Kouros Owzar, Sherrie Lessans, et al.
Biorxiv : the Preprint Server for Biology
|
February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancer
A Mandl, S Jasmine, Teg Krueger, et al.
Cancer
|
December 1, 2024
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Alan H Bryce, Neeraj Agarwal, Himisha Beltran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, et al.
The Lancet. Oncology
|
August 21, 2019
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert J Motzer, Brian I Rini, David F McDermott, et al.
European Urology
|
December 20, 2016
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death
Rong Na, S Lilly Zheng, Misop Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2025
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
Jarey H Wang, Alexander D Sherry, Soha Bazyar, et al.
Page
of 39